Cost-benefit approach in evaluating investment into donor action: The German case

Leo Roels, Z. Kaló, Detlef Boesebeck, James Whiting, Celia Wight

Research output: Article

19 Citations (Scopus)

Abstract

Donor Action (DA) is an international initiative to help critical care units (CCUs) increase their own donation rates through improved-quality donation practices. Following a validated diagnostic review (DR), areas of weakness can be identified, and the appropriate changes introduced. Data gathered from a number of centers in nine European countries (including Germany) 1 year after the introduction of targeted improvement measures demonstrated a 59.2% (P = 0.0015) increase in donation rates. This analysis computes the cost-benefit thresholds of implementing the DA methodology from a German health-economic point of view, taking into account the treatment alternatives for end-stage renal disease (dialysis and transplantation) and comparing the DA program with current organ-donation practice. Lifetime direct medical costs and quality-adjusted life years (QALYs) were calculated for both arms, considering only changes in cadaveric renal transplantation rates. If DA leads to a 59% overall increase in organ donation in Germany, the program will result in 33 QALYs and 1.8-million euros cost savings per million population (PMP). Therefore, DA would be cost-effective below 2.66-million euros implementation cost PMP (or 218-million euros for the whole country). As the partial implementation cost of the program was far below the threshold, DA is more cost-effective than other publicly reimbursed medical intervention.

Original languageEnglish
Pages (from-to)321-326
Number of pages6
JournalTransplant International
Volume16
Issue number5
DOIs
Publication statusPublished - máj. 1 2003

Fingerprint

Cost-Benefit Analysis
Costs and Cost Analysis
Tissue and Organ Procurement
Quality-Adjusted Life Years
Kidney Transplantation
Germany
Cost Savings
Critical Care
Population
Chronic Kidney Failure
Renal Dialysis
Economics
Health
Therapeutics

ASJC Scopus subject areas

  • Transplantation

Cite this

Cost-benefit approach in evaluating investment into donor action : The German case. / Roels, Leo; Kaló, Z.; Boesebeck, Detlef; Whiting, James; Wight, Celia.

In: Transplant International, Vol. 16, No. 5, 01.05.2003, p. 321-326.

Research output: Article

Roels, Leo ; Kaló, Z. ; Boesebeck, Detlef ; Whiting, James ; Wight, Celia. / Cost-benefit approach in evaluating investment into donor action : The German case. In: Transplant International. 2003 ; Vol. 16, No. 5. pp. 321-326.
@article{79252e6e7cac4d91bee856bf683274d8,
title = "Cost-benefit approach in evaluating investment into donor action: The German case",
abstract = "Donor Action (DA) is an international initiative to help critical care units (CCUs) increase their own donation rates through improved-quality donation practices. Following a validated diagnostic review (DR), areas of weakness can be identified, and the appropriate changes introduced. Data gathered from a number of centers in nine European countries (including Germany) 1 year after the introduction of targeted improvement measures demonstrated a 59.2{\%} (P = 0.0015) increase in donation rates. This analysis computes the cost-benefit thresholds of implementing the DA methodology from a German health-economic point of view, taking into account the treatment alternatives for end-stage renal disease (dialysis and transplantation) and comparing the DA program with current organ-donation practice. Lifetime direct medical costs and quality-adjusted life years (QALYs) were calculated for both arms, considering only changes in cadaveric renal transplantation rates. If DA leads to a 59{\%} overall increase in organ donation in Germany, the program will result in 33 QALYs and 1.8-million euros cost savings per million population (PMP). Therefore, DA would be cost-effective below 2.66-million euros implementation cost PMP (or 218-million euros for the whole country). As the partial implementation cost of the program was far below the threshold, DA is more cost-effective than other publicly reimbursed medical intervention.",
keywords = "Cost-benefit/cost-effectiveness analysis, Organ donation, Quality assurance",
author = "Leo Roels and Z. Kal{\'o} and Detlef Boesebeck and James Whiting and Celia Wight",
year = "2003",
month = "5",
day = "1",
doi = "10.1111/j.1432-2277.2003.tb00307.x",
language = "English",
volume = "16",
pages = "321--326",
journal = "Transplant International",
issn = "0934-0874",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Cost-benefit approach in evaluating investment into donor action

T2 - The German case

AU - Roels, Leo

AU - Kaló, Z.

AU - Boesebeck, Detlef

AU - Whiting, James

AU - Wight, Celia

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Donor Action (DA) is an international initiative to help critical care units (CCUs) increase their own donation rates through improved-quality donation practices. Following a validated diagnostic review (DR), areas of weakness can be identified, and the appropriate changes introduced. Data gathered from a number of centers in nine European countries (including Germany) 1 year after the introduction of targeted improvement measures demonstrated a 59.2% (P = 0.0015) increase in donation rates. This analysis computes the cost-benefit thresholds of implementing the DA methodology from a German health-economic point of view, taking into account the treatment alternatives for end-stage renal disease (dialysis and transplantation) and comparing the DA program with current organ-donation practice. Lifetime direct medical costs and quality-adjusted life years (QALYs) were calculated for both arms, considering only changes in cadaveric renal transplantation rates. If DA leads to a 59% overall increase in organ donation in Germany, the program will result in 33 QALYs and 1.8-million euros cost savings per million population (PMP). Therefore, DA would be cost-effective below 2.66-million euros implementation cost PMP (or 218-million euros for the whole country). As the partial implementation cost of the program was far below the threshold, DA is more cost-effective than other publicly reimbursed medical intervention.

AB - Donor Action (DA) is an international initiative to help critical care units (CCUs) increase their own donation rates through improved-quality donation practices. Following a validated diagnostic review (DR), areas of weakness can be identified, and the appropriate changes introduced. Data gathered from a number of centers in nine European countries (including Germany) 1 year after the introduction of targeted improvement measures demonstrated a 59.2% (P = 0.0015) increase in donation rates. This analysis computes the cost-benefit thresholds of implementing the DA methodology from a German health-economic point of view, taking into account the treatment alternatives for end-stage renal disease (dialysis and transplantation) and comparing the DA program with current organ-donation practice. Lifetime direct medical costs and quality-adjusted life years (QALYs) were calculated for both arms, considering only changes in cadaveric renal transplantation rates. If DA leads to a 59% overall increase in organ donation in Germany, the program will result in 33 QALYs and 1.8-million euros cost savings per million population (PMP). Therefore, DA would be cost-effective below 2.66-million euros implementation cost PMP (or 218-million euros for the whole country). As the partial implementation cost of the program was far below the threshold, DA is more cost-effective than other publicly reimbursed medical intervention.

KW - Cost-benefit/cost-effectiveness analysis

KW - Organ donation

KW - Quality assurance

UR - http://www.scopus.com/inward/record.url?scp=0038409926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038409926&partnerID=8YFLogxK

U2 - 10.1111/j.1432-2277.2003.tb00307.x

DO - 10.1111/j.1432-2277.2003.tb00307.x

M3 - Article

C2 - 12759723

AN - SCOPUS:0038409926

VL - 16

SP - 321

EP - 326

JO - Transplant International

JF - Transplant International

SN - 0934-0874

IS - 5

ER -